Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial.

@article{McRaeClark2015BuspironeTO,
  title={Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial.},
  author={Aimee L. McRae-Clark and Nathaniel L. Baker and Kevin M. Gray and Therese K. Killeen and Amanda Marie Wagner and Kathleen T. Brady and C Lindsay DeVane and Jessica Norton},
  journal={Drug and alcohol dependence},
  year={2015},
  volume={156},
  pages={
          29-37
        }
}
BACKGROUND The purpose of this study was to evaluate the efficacy of buspirone, a partial 5-HT1A agonist, for treatment of cannabis dependence. METHODS One hundred seventy-five cannabis-dependent adults were randomized to receive either up to 60mg/day of buspirone (n=88) or placebo (n=87) for 12 weeks combined with a brief motivational enhancement therapy intervention and contingency management to encourage study retention. Cannabis use outcomes were assessed via weekly urine cannabinoid… CONTINUE READING
6
Twitter Mentions

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 16 CITATIONS

Current drug treatments targeting dopamine D3 receptor.

VIEW 18 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal

VIEW 4 EXCERPTS
CITES BACKGROUND, RESULTS & METHODS
HIGHLY INFLUENCED